-
1.发明申请PROCESS FOR THE DETERMINATION OF THE PRIMARY STRUCTURE OF THE MESSENGER RNA CODING FOR THE HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (HEOPA) [AF217798]... 审中-公开确定人类重组内源性Aβ（HEOPA）的信使RNA编码的主要结构的方法[AF217798]
公开(公告)号：WO2004053052A2
公开(公告)日：2004-06-24
申请号：PCT/BR2003/000189
申请日：2003-12-08
Applicant: CAMARGO, Antônio , HAYASHI, Mirian , PORTARO, Fernanda , GUERREIRO, Juliano
Inventor： CAMARGO, Antônio , HAYASHI, Mirian , PORTARO, Fernanda , GUERREIRO, Juliano
IPC: C12N
CPC classification number: C12N9/6421
Abstract: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies.
Abstract translation: 本发明涉及编码hEOPA多核苷酸的重组人内寡肽酶（hEOPA）多核苷酸，其允许在原核生物和真核生物（包括人）中表达EOPA; 使用合成底物来测定hEOPA的蛋白水解活性，或其伴侣活性或其作为可溶性肽受体的活性; 获得和使用其寡肽结合活性的特异性抗体和抑制剂作为激动剂，竞争剂和拮抗剂，其能够干扰其相互作用和与其它蛋白质的复合物形成。 本发明还涉及化学或遗传修饰的天然和重组蛋白质的应用，其目的是诊断和/或在中枢神经系统的先天性，感染性和退行性病理状况中的应用，以及精神和行为功能障碍。 还提出抑制剂和竞争剂在EOPA与配体（包括抗体或其衍生物）的相互作用中的应用用于治疗组织和神经退行性病变。
-
公开(公告)号：WO2008080200A1
公开(公告)日：2008-07-10
申请号：PCT/BR2006/000309
申请日：2006-12-29
Applicant: KERKIS, Irina , KERKIS, Alexandre , HAYASHI, Mirian Akemi Furuie , CERRUTI, Humberto F.
CPC classification number: C12N5/0664
Abstract: THE PRESENT INVENTION REFERS TO A PROCESS FOR OBTAINMENT OF ADULT STEM CELLS, PRESENTING CHARACTERISTICS OF EMBRYONIC STEM CELLS, FROM POSTNATAL AND ADULT TISSUES; TO ADULT STEM CELLS THAT PRESENT CHARACTERISTICS OF EMBRYONIC STEM CELLS; TO AN ADVANTAGEOUS PROCESS IN THE DIFFERENTIATION OF STEM CELLS AND, TO DIFFERENTIATED CELLS OBTAINED FROM SAID PROCESS. THE PRESENT INVENTION ALSO REFERS TO THE NUMEROUS POSSIBILITIES OF APPLICATION OF SAID CELLS, WHETHER OR NOT DIFFERENTIATED: THERAPEUTIC AND NON-THERAPEUTIC, BIOTECHNOLOGICAL AND PHARMACEUTICAL, RESULTING FROM THE DEVELOPMENT ACHIEVED BY THE INVENTORS.
Abstract translation: 本发明涉及用于获得成熟干细胞的方法，从后期和成年组织提出胚胎干细胞的特征; 建立胚胎干细胞的特征的成熟干细胞; 对于干细胞分化和从分化过程中获得的差异细胞的有利过程。 本发明还涉及根据发明人所发展的结果，可以应用不同的细胞，不论是否具有差异：治疗和非治疗，生物技术和药物的可能性。
-
公开(公告)号：WO2006096953A1
公开(公告)日：2006-09-21
申请号：PCT/BR2006/000052
申请日：2006-03-17
Applicant: FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP - Attn.: Dr. Carlos Alberto Vogt , YAMANE, Tetsuo , KERKIS, Irina , KERKIS, Alexandre , BAPTISTA, Gandhi, Rádis , HAYASHI, Mirian, Akemi, Furuie , KONNO, Katsuhiro , DA SILVA, Alvaro, Rossan, B., P. , PEREIRA, Lygia, da Veiga , DE OLIVEIRA, Eduardo, Brandt
Inventor： YAMANE, Tetsuo , KERKIS, Irina , KERKIS, Alexandre , BAPTISTA, Gandhi, Rádis , HAYASHI, Mirian, Akemi, Furuie , KONNO, Katsuhiro , DA SILVA, Alvaro, Rossan, B., P. , PEREIRA, Lygia, da Veiga , DE OLIVEIRA, Eduardo, Brandt
CPC classification number: A61K9/0019 , A61K38/17 , A61K47/02 , A61K47/62 , A61K47/6951 , A61K49/0032 , A61K49/0047 , A61K49/0056 , B82Y5/00 , C07K14/46
Abstract: The present invention refers to uses of crotamine and compositions containing it, based on its characteristic of interaction with genetic material. Under submicromolar quantities, the polypeptide is no longer toxic, presenting the characteristics properties of cell penetration, transport of molecules to the surface, cytoplasm or cell nucleus and particularly, selective cell penetration. The invention also refers to compositions comprising a pharmaceutically effective concentration of crotamine and its use for the treatment of diseases and dysfunctions, based on its characteristics of interaction with genetic material, such as DNA and RNA, and cell selectivity. Further, the invention refers to a kit comprising crotamine as a reagent to: (i) transfect or carry molecules to the surface, cytoplasm or nucleus of the cell or (ii) identify and select actively proliferating cells in a mixed cell population, particularly the ones originated from the umbilical cord and/or bone marrow.
Abstract translation: 本发明是基于其与遗传物质相互作用的特征，涉及含有它的巴罗门胺及其组合物的用途。 在亚微摩尔量下，多肽不再具有毒性，呈现细胞渗透，分子转移到表面，细胞质或细胞核的特征，特别是选择性细胞穿透。 本发明还涉及基于其与遗传物质如DNA和RNA的相互作用特性以及细胞选择性的包含药物有效浓度的小肠的组合物及其用于治疗疾病和功能障碍的用途。 此外，本发明涉及一种试剂盒，其包含作为试剂的基肠蛋白，以：（i）将细胞转染或携带到细胞的表面，细胞质或细胞核或（ii）在混合细胞群体中识别并选择主动增殖的细胞，特别是 起源于脐带和/或骨髓。
-
4.发明申请METHOD AND KIT FOR DIAGNOSING NEUROPSYCHIATRIC CONDITIONS, METHOD FOR EVALUATING TREATMENTS OF NEUROPSYCHIATRIC CONDITIONS, AND METHOD FOR IDENTIFYING PHARMACEUTICALS THAT ARE POTENTIALLY USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC CONDITIONS 审中-公开用于诊断神经营养障碍病症的方法和工具包，用于评估神经病学治疗条件的治疗方法，以及用于鉴定可能用于治疗神经营养障碍症状的药物的方法
公开(公告)号：WO2012061914A3
公开(公告)日：2012-09-13
申请号：PCT/BR2011000417
申请日：2011-11-09
Applicant: UNIV FED SAO PAULO UNIFESP , FURUIE HAYASHI MIRIAN AKEMI , AFFONSECA BRESSAN RODRIGO , SILVEIRA BUENO BRANDAO DE OLIVEIRA VITOR MARCELO , GADELHA DE ALENCAR ARARIPE NETO ARY , FERREIRA MARCONDES MACHADO MAURICIO
Inventor： FURUIE HAYASHI MIRIAN AKEMI , AFFONSECA BRESSAN RODRIGO , SILVEIRA BUENO BRANDAO DE OLIVEIRA VITOR MARCELO , GADELHA DE ALENCAR ARARIPE NETO ARY , FERREIRA MARCONDES MACHADO MAURICIO
IPC: C12Q1/37
CPC classification number: C12Q1/37
Abstract: The present invention relates to a diagnostic assay and kit for carrying out the assay, useful for diagnosing neuropsychiatric conditions, in particular schizophrenia, on the basis of the activity of the Ndel1 enzyme. The present invention also provides a method for evaluating the effectiveness of treatments of these conditions, and for identifying pharmaceuticals that are potentially useful for treating these conditions.
Abstract translation: 本发明涉及用于进行该测定的诊断测定和试剂盒，其用于诊断神经精神病症，特别是精神分裂症，其基于Ndel1酶的活性。 本发明还提供了用于评价这些病症的治疗有效性的方法，以及用于鉴定潜在可用于治疗这些病症的药物的方法。
-
Patent Agency Ranking5.发明申请PHARMACEUTICAL COMPOSITIONS OF PEPTIDES, SECRETED BY THE VENOM GLANDS OF SNAKES, ESPECIALLY BOTHROPS JARARACA, EVASINS, ANALOGUES, DERIVATIVES AND ASSOCIATED PRODUCTS FOR EMPLOYMENT AS MODULATORS OF ACETYLCHOLINE RECEPTOR FUNCTION. 审中-公开由蛇毒VENOM GLANDS分泌的肽的药物组合物，特别是JARARACA，EVASINS，类似物，衍生物和用于作为乙酰胆碱受体功能调节剂的相关产品的组合物。
公开(公告)号：WO2005081613A2
公开(公告)日：2005-09-09
申请号：PCT/BR2005/000015
申请日：2005-02-04
Applicant: BIOLAB SANUS FARMACÊUTICA LTDA. , FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP , HAYASHI, Mirian Akemi Furuie , CAMARGO, Antonio Carlos Martins de , ULRICH, Alexander Henning , MILLÁN, Rubén Dario Sinisterra , SANTOS, Robson Augusto Souza dos , IANZER, Danielle Alves , MARIONI, Raphael dos Reis , SILVA, Carlos Alberto da
Inventor： HAYASHI, Mirian Akemi Furuie , CAMARGO, Antonio Carlos Martins de , ULRICH, Alexander Henning , MILLÁN, Rubén Dario Sinisterra , SANTOS, Robson Augusto Souza dos , IANZER, Danielle Alves , MARIONI, Raphael dos Reis , SILVA, Carlos Alberto da
Abstract: The present invention refers to the employment of pharmaceutical compositions of snake venom glands secreted peptides, particularly from Bothrops jararaca, EVASINS, and analogous and derivatives compounds, and associated products, as modulating agents of the acetylcholine receptors. The pharmaceutical compositions of the present invention are characterized by acting as agonist, partial agonist, antagonist or alosteric modulators of the acetylcholine receptors. The pharmaceutical compostions of EVASINS also refer to the use of these compounds to protect the acetycholine receptors against the action of toxins, such as the phylantotoxins or cembranoids isolated from the coral or tobacco, or also spider toxins. The pharmaceutical compositions of EVASINS are characterized by the ability to prevent the binding of the cocaine to the acetylcholine receptors. The pharmaceutical compostions of EVASINS and their structural and/or conformational analogues characterized by the employment of EVASINS and their respective analogues and derivatives refer to the use as molecular models for the development of drugs and/or pharmaceutical compositions based on peptidic and/or non-peptidic compounds for the use in the diagnosis, prevention, study and treatment of diseases associated with the cholinergic receptors disfunctions. The pharmaceutical compositions of the mentioned EVASINS, analogues and derivatives included into cyclodextrins and derivatives, of the present patent show an increase of the biodisponibility, duration and/or efficacy of the modulating effects on the acetylcholine receptors once inoculated by different administration routes such as oral, intravenous, intramuscle, nasal, subcutaneous, transdermic, as non-limiting examples.
Abstract translation: 本发明涉及使用蛇毒腺分泌肽的药物组合物，特别是来自Bothrops jararaca，EVASINS以及类似和衍生物化合物以及相关产物作为乙酰胆碱受体的调节剂。 本发明的药物组合物的特征在于充当乙酰胆碱受体的激动剂，部分激动剂，拮抗剂或变构调节剂。 EVASINS的药物组合物还涉及使用这些化合物保护乙酰胆碱受体免于毒素的作用，例如从珊瑚或烟草中分离的乙基毒素或西松烷类，或者还有蜘蛛毒素。 EVASINS的药物组合物的特征在于能够防止可卡因与乙酰胆碱受体结合。 以使用EVASINS及其各自的类似物和衍生物为特征的EVASINS及其结构和/或构象类似物的药物组合物指作为分子模型用于开发基于肽和/或非肽的药物和/或药物组合物的分子模型， 用于诊断，预防，研究和治疗与胆碱能受体功能障碍相关的疾病。 本专利提及的包含在环糊精和衍生物中的所提及的EVASINS，其类似物和衍生物的药物组合物显示一旦通过不同的给药途径例如口服接种，对乙酰胆碱受体的调节作用的生物指数，持续时间和/或功效增加 ，静脉内，肌内，鼻内，皮下，透皮，作为非限制性实例。
-
6.发明申请
公开(公告)号：WO2012061914A2
公开(公告)日：2012-05-18
申请号：PCT/BR2011/000417
申请日：2011-11-09
Applicant: UNIVERSIDADE FEDERAL DE SÃO PAULO - UNIFESP , FURUIE HAYASHI, Mirian Akemi , AFFONSECA BRESSAN, Rodrigo , SILVEIRA BUENO BRANDÃO DE OLIVEIRA, Vitor Marcelo , GADELHA DE ALENCAR ARARIPE NETO, Ary , FERREIRA MARCONDES MACHADO, Mauricio
Inventor： FURUIE HAYASHI, Mirian Akemi , AFFONSECA BRESSAN, Rodrigo , SILVEIRA BUENO BRANDÃO DE OLIVEIRA, Vitor Marcelo , GADELHA DE ALENCAR ARARIPE NETO, Ary , FERREIRA MARCONDES MACHADO, Mauricio
IPC: C12Q1/37
CPC classification number: C12Q1/37
Abstract: A presente invenção está relacionada a um teste diagnóstico e um kit para realização deste teste, que são úteis para diagnóstico de condições neuropsiquiátricas, em especial no diagnóstico da esquizofrenia, baseado na atividade da enzima Ndel1. A presente invenção ainda proporciona um método para a avaliação da eficácia de tratamentos dessas condições, bem como a identificação de fármacos com potencial no tratamento dessas condições.
Abstract translation: 本发明的特征在于本发明涉及本发明的用途。 相关的DIAGN＆oacute测试;脓毒性以及执行MAKE-手中，该试验中，是HANDS的试剂盒;所述＆uacute;对于DIAGN＆oacute有用;条件＆ccedil脓毒性;＆otilde; S neuropsiquiá营养，特别DIAGN＆oacute;脓毒性精神分裂症，基于 在酶Ndel1的活性中。 本发明MAKE-手中，还提供了一种M＆eacute;所有的评估MAKE-手中，EFICá处理复制这些条件＆ccedil;＆otilde; S和识别MAKE-HANDS，在这些治疗中的F A rmacos潜在 条件。
-
公开(公告)号：WO2004053052A3
公开(公告)日：2006-08-03
申请号：PCT/BR0300189
申请日：2003-12-08
Applicant: CAMARGO ANTONIO , HAYASHI MIRIAN , PORTARO FERNANDA , GUERREIRO JULIANO
Inventor： CAMARGO ANTONIO , HAYASHI MIRIAN , PORTARO FERNANDA , GUERREIRO JULIANO
IPC: C12N9/64
CPC classification number: C12N9/6421
Abstract: This invention refers to a process for the determination of the primary structure of the mRNA coding for human endooligopeptidase A (hEOPA) and its protein sequence. In addition, the invention relates to a process for the determination of the structure of the hEOPA gene and the production of recombinant hEOPA. Furthermore, the invention relates to a process of generating antibodies against hEOPA in mice.
Abstract translation: 本发明涉及确定编码人内寡肽酶A（hEOPA）的mRNA及其蛋白质序列的一级结构的方法。 此外，本发明涉及确定hEOPA基因的结构和重组hEOPA的产生的方法。 此外，本发明涉及在小鼠中产生针对hEOPA的抗体的方法。
-
8.发明申请PHARMACEUTICAL COMPOSITIONS OF PEPTIDES SECRETED BY THE VENOM GLANDS OF SNAKES 审中-公开通过血管内皮细胞分泌的肽的药物组合物
公开(公告)号：WO2005081613A3
公开(公告)日：2005-10-13
申请号：PCT/BR2005000015
申请日：2005-02-04
Applicant: BIOLAB SANUS FARMACEUTICA LTDA , FUNDACAO DE AMPARO A PESQUISA , HAYASHI MIRIAN AKEMI FURUIE , CAMARGO ANTONIO CARLOS MARTINS , ULRICH ALEXANDER HENNING , MILLAN RUBEN DARIO SINISTERRA , SANTOS ROBSON AUGUSTO SOUZA DO , IANZER DANIELLE ALVES , MARIONI RAPHAEL DOS REIS , SILVA CARLOS ALBERTO DA
Inventor： HAYASHI MIRIAN AKEMI FURUIE , CAMARGO ANTONIO CARLOS MARTINS , ULRICH ALEXANDER HENNING , MILLAN RUBEN DARIO SINISTERRA , SANTOS ROBSON AUGUSTO SOUZA DO , IANZER DANIELLE ALVES , MARIONI RAPHAEL DOS REIS , SILVA CARLOS ALBERTO DA
Abstract: The present invention refers to the employment of pharmaceutical compositions of snake venom glands secreted peptides, particularly from Bothrops jararaca, EVASINS, and analogous and derivatives compounds, and associated products, as modulating agents of the acetylcholine receptors. The pharmaceutical compositions of EVASINS are characterized by the ability to prevent the binding of the cocaine to the acetylcholine receptors.
Abstract translation: 本发明涉及使用蛇毒腺体分泌肽的药物组合物，特别是来自Bothrops jararaca，EVASINS，以及类似和衍生物化合物及其相关产品作为乙酰胆碱受体的调节剂。 EVASINS的药物组合物的特征在于防止可卡因与乙酰胆碱受体结合的能力。
-
公开(公告)号：WO2002074782A3
公开(公告)日：2002-09-26
申请号：PCT/BR2002/000041
申请日：2002-03-18
Applicant: BIOLAB SANUS FARMACÊUTICA LTDA. , FUNDACÃO DE AMPARO À PESQUISA DO ESTADO DE SÂO PAULO - FAPESP , MARTINS DE CAMARGO, Antônio, Carlos , CALHETA VIEIRA PORTARO, Fernanda , FERRAGINI MURBACK, Alessandra , ALVES IANZER, Danielle , POLISELLI FARSKY, Sandra, Helena , PALMA, Mario, Sergio , HAYASHI, Mirian Akemi Furuie
Inventor： MARTINS DE CAMARGO, Antônio, Carlos , CALHETA VIEIRA PORTARO, Fernanda , FERRAGINI MURBACK, Alessandra , ALVES IANZER, Danielle , POLISELLI FARSKY, Sandra, Helena , PALMA, Mario, Sergio , HAYASHI, Mirian Akemi Furuie
Abstract: The present invention patent refers to the isolation and purification of peptides secreted by serpent venom glands, specifically Bothrops jararaca ; to the peptide thus obtained, as well as to the production procedures by genetic engineering techniques in procaryotic and eukaryotic systems; to the engineered peptide thus obtained; to the production of said peptide by chemical synthesis, as well as to the peptide resulting from this chemical processing. It also refers to the utilization of said peptides, obtained by different procedures, in distinct pharmaceutical compositions, and introduced into the organism by a variety of means, in order for them to act as inhibitors of vasopeptidases, and consequently reduce systemic arterial blood pressure, and show local vasodilating action.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.01 seconds)
